General
Preferred name
BEXAROTENE
Synonyms
LG-100069,LGD-1069 ()
LGD1069 ()
Targretin ()
Ro 26-4455 ()
Bexarotene (LGD1069) ()
LG-100069 ()
NSC-747528 ()
LGD-1069 ()
Targretine ()
LG100069 ()
Bexarotene-d4 ()
P&D ID
PD003617
CAS
153559-49-0
2182068-00-2
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
1999
Drug Status
investigational
approved
Drug indication
Cutaneous T-cell lymphoma
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Bexarotene is a retinoid that selectively activates retinoid X receptors (RXRs), used for its antineoplastic action.
DESCRIPTION Bexarotene is a retinoid that selectively activates retinoid X receptors (RXRs), and is used for its antineoplastic action. (GtoPdb)
DESCRIPTION inhibitor of retinoid X receptors (Informer Set)
DESCRIPTION Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma. (BOC Sciences Bioactive Compounds)
DESCRIPTION Nurr1 activator; inhibits NF-kappaB-dependent gene expression (Tocris Bioactive Compound Library)
Cell lines
305
Organisms
0
Compound Sets
33
AdooQ Bioactive Compound Library
A11094
Axon Medchem Screening Library
1700
BOC Sciences Bioactive Compounds
bexarotene-cas-153559-49-0-item-84-59629
Cayman Chemical Bioactives
11571
22610
ChEMBL Approved Drugs
CHEMBL1023
ChEMBL Drugs
CHEMBL1023
Concise Guide to Pharmacology 2017/18
2807
Concise Guide to Pharmacology 2019/20
2807
Concise Guide to Pharmacology 2021/22
2807
Concise Guide to Pharmacology 2023/24
2807
Drug Repurposing Hub
DrugBank
DB00307
DrugBank Approved Drugs
DB00307
DrugCentral
361
DrugCentral Approved Drugs
361
DrugMAP
DMOBIKY
DrugMAP Approved Drugs
DMOBIKY
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101376
Guide to Pharmacology
2807
Informer Set
374747
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1023
MedChem Express Bioactive Compound Library
HY-14171
NCATS Inxight Approved Drugs
A61RXM4375
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2FPXQH4UEUBU
ReFrame library
Selleckchem Bioactive Compound Library
bexarotene
TargetMol Bioactive Compound Library
T6410
The Spectrum Collection
Tocris Bioactive Compound Library
5819
Welcome Trust Cancer Drugs
186
ZINC Tool Compounds
ZINC000001539579
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
348.21
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
6.1
TPSA
37.3
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
RXRA
RXRB
RXRG
Retinioic acid X family agonist
RXR
RXRA, RXRB, RXRG
RXR antagonist
RAR/RXR
Retinoid Receptor
Compound status
FDA
Pathway
Metabolism
Autophagy
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Primary Target
Retinoid X Receptors
MOA
Agonist
Retinoid Receptor agonist
Indication
cutaneous T-cell lymphoma (CTCL)
Therapeutic Class
Anticancer Agents
Source data